BACKGROUND: The aim of this study was to assess the influence of tobacco exposure, at the time of diagnosis, on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma (TCC) of the bladder. METHODS: A retrospective cohort study was performed using the MSKCC Registry to identify all institutional cases of "noninvasive" TCC (n = 1632) between 1985 and 1995. After employing exclusion criteria, 286 cases of incident tobacco-associated superficial TCC were divided into 3 strata of tobacco exposure (127 ex-smokers, 51 quitters, and 108 continued smokers) by chart review and post hoc questionnaires (n = 82). Measured outcomes included recurrence free survival and survival free of adverse events (defined a priori as disease progression or other urinary tract TCC). RESULTS: There were no significant differences among ex-smokers, quitters, and continued smokers in terms of stage, grade, tumor size, multifocality, up-front bacillus Calmette-Guérin therapy, or median follow-up. Ex-smokers presented at a later age than individuals who continued to smoke. Post hoc questionnaires and chart reviews were compared in terms of smoking status at time of diagnosis, and reliability was excellent (kappa = 0.89). Multivariate analyses revealed diminished recurrence free survival among continued smokers versus quitters or ex-smokers. Univariate analyses revealed diminished adverse event free survival among continued smokers versus quitters or ex-smokers. Multivariate models assessing adverse event free survival revealed a similar trend (P = 0.06). CONCLUSIONS: Continued smokers experience worse disease-associated outcomes than patients who quit smoking. Smoking cessation should thus be employed as a tertiary prevention strategy for patients with superficial TCC. Copyright 1999 American Cancer Society.
BACKGROUND: The aim of this study was to assess the influence of tobacco exposure, at the time of diagnosis, on the disease-related outcomes of patients with tobacco-associated superficial transitional cell carcinoma (TCC) of the bladder. METHODS: A retrospective cohort study was performed using the MSKCC Registry to identify all institutional cases of "noninvasive" TCC (n = 1632) between 1985 and 1995. After employing exclusion criteria, 286 cases of incident tobacco-associated superficial TCC were divided into 3 strata of tobacco exposure (127 ex-smokers, 51 quitters, and 108 continued smokers) by chart review and post hoc questionnaires (n = 82). Measured outcomes included recurrence free survival and survival free of adverse events (defined a priori as disease progression or other urinary tract TCC). RESULTS: There were no significant differences among ex-smokers, quitters, and continued smokers in terms of stage, grade, tumor size, multifocality, up-front bacillus Calmette-Guérin therapy, or median follow-up. Ex-smokers presented at a later age than individuals who continued to smoke. Post hoc questionnaires and chart reviews were compared in terms of smoking status at time of diagnosis, and reliability was excellent (kappa = 0.89). Multivariate analyses revealed diminished recurrence free survival among continued smokers versus quitters or ex-smokers. Univariate analyses revealed diminished adverse event free survival among continued smokers versus quitters or ex-smokers. Multivariate models assessing adverse event free survival revealed a similar trend (P = 0.06). CONCLUSIONS: Continued smokers experience worse disease-associated outcomes than patients who quit smoking. Smoking cessation should thus be employed as a tertiary prevention strategy for patients with superficial TCC. Copyright 1999 American Cancer Society.
Authors: Dragan J Golijanin; David Kakiashvili; Ralph R Madeb; Edward M Messing; Seth P Lerner Journal: World J Urol Date: 2006-11 Impact factor: 4.226
Authors: Asaf Wyszynski; Sam A Tanyos; Judy R Rees; Carmen J Marsit; Karl T Kelsey; Alan R Schned; Eben M Pendleton; Maria O Celaya; Michael S Zens; Margaret R Karagas; Angeline S Andrew Journal: Cancer Date: 2013-10-10 Impact factor: 6.860
Authors: Elyse R Park; Jamie S Ostroff; Giselle K Perez; Kelly A Hyland; Nancy A Rigotti; Sarah Borderud; Susan Regan; Alona Muzikansky; Emily R Friedman; Douglas E Levy; Susan Holland; Justin Eusebio; Lisa Peterson; Julia Rabin; Jacob Miller-Sobel; Irina Gonzalez; Laura Malloy; Maureen O'Brien; Suhana de León-Sanchez; C Will Whitlock Journal: Contemp Clin Trials Date: 2016-07-19 Impact factor: 2.226
Authors: Michael Rink; Evanguelos Xylinas; Vitaly Margulis; Eugene K Cha; Behfar Ehdaie; Jay D Raman; Felix K Chun; Kazumasa Matsumoto; Yair Lotan; Helena Furberg; Marek Babjuk; Armin Pycha; Christopher G Wood; Pierre I Karakiewicz; Margit Fisch; Douglas S Scherr; Shahrokh F Shariat Journal: Eur Urol Date: 2012-06-22 Impact factor: 20.096
Authors: Sebastiano La Maestra; Rosanna T Micale; Silvio De Flora; Francesco D'Agostini; Gancho Ganchev; Marietta Iltcheva; Nikolay Petkov; Vernon E Steele; Roumen Balansky Journal: Carcinogenesis Date: 2012-10-05 Impact factor: 4.944